Serum lipoprotein profile in newly recognized arterial hypertension. The role of atherogenic lipoproteins in the pathogenesis of disease;Lipoproteínový profil séra pri novozistenej artériovej hypertenzii. Úloha aterogénnych lipoproteínov v patogenéze ochorenia

Vnitrni Lekarstvi

Volumn 56, Issue 9, 2010, Pages 967-971

  Oravec, Stanislav ^a   Dukat A ^a   Gavornik P ^a   Caprdna M ^a   Kucera M ^a  

^a II Interná Klinika Lekárskej Fakulty UK a FNsP Bratislava   (Slovakia)

Author keywords

Atherogenic lipoprotein profile; Atherogenic normolipemia; Non atherogenic hypercholesterolemia

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LABORATORY DIAGNOSIS; LIPOPROTEIN BLOOD LEVEL; PATHOGENESIS; PHENOTYPE;

ATHEROSCLEROSIS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 77957930744     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Felmeden DC, Spencer CG, Blann AD et al. Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment. Hypertension 2003; 41: 528-533.
2. Whitworth JA. World Health Organisation (WHO), International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertension 2003; 21: 1983-1992.
3. Horký K. Systémová arteriální hypertenze. In: Klenner P et al (eds). Vnitřni lékař ství. Praha: Galén 1998: 137-149.
4. Rubies-Prat J, Ordónez-Llanos J, Martin S et al. Low-density lipoprotein particle size, triglyceride-rich lipoproteins and glucose tolerance in non-diabetic men with essential hypertension. Clin Exp Hypertens 2001; 23: 489-500.
5. Landray MJ, Edmunds E, Li-Saw-Hee FL et al. Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension. QJM 2002; 95: 165-171.
6. Zhao CX, Cui YH, Fan Q et al. Small dense low-density lipoproteins and associated risk factors in patients with stroke. Cerebrovasc Dis 2009; 27: 99-104.
7. Austin MA. Triglyceride, small dense low-density lipoprotein and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2: 200-207.
8. Van J, Pan J, Charles MA et al. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131: 1679-1685.
9. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 395-403.
10. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363-1379.
11. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-1069.
12. Shoji T, Hatsuda S, Tsuchikura S et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202: 582-588.
13. Hoefner DM, Hodel SD, O'Brien JF et al. Development of a rapid quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem 2001; 472: 266-274.
14. Oravec S. Nova laboratórno-medicínska pomoc v diagnostike dyslipoproteínemií a kardiovaskulárnych ochorení: Identifikácia LDL podskupín. Med Milit Slov 2006; 8: 28-32.
15. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
16. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. AmJ Cardiol 2000; 86: 943-949.
17. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-1069.
18. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749.
19. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A.
20. Oravec S. Identifikácia subpopulácií LDL triedy - Aktuálny prínos v diagnostike porúch metabolizmu lipoproteínov a ochorení kardiovaskulárneho systému. Med Milit Slov 2006; 8: 32-34.
21. Oravec S. Nové perspektívy v diagnostike porúch metabolizmu lipoproteínov - prínos v interpretácii výsledkov. Med Milit Slov 2007; 9: 42-45.
22. Oravec S. Nové možnosti posúdenia kardiovaskulárneho rizika u pacientov s obezitou a metabolickými ochoreniami. Med Milit Slov 2007; 9: 46-49.
23. Oravec S. Den drohenden Herztod erkennen - und vermeiden. Der Mediziner 2010; 4: 6-7.